BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20230629)

  • 1. Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.
    Hendriks BS; Seidl KM; Chabot JR
    BMC Syst Biol; 2010 Mar; 4():23. PubMed ID: 20230629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors.
    Williams RG; Kandasamy R; Nickischer D; Trask OJ; Laethem C; Johnston PA; Johnston PA
    Methods Enzymol; 2006; 414():364-89. PubMed ID: 17110203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1.
    Ember B; Kamenecka T; LoGrasso P
    Biochemistry; 2008 Mar; 47(10):3076-84. PubMed ID: 18269248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and characterization of a substrate selective p38alpha inhibitor.
    Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
    Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800.
    Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M
    Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catalysis and function of the p38 alpha.MK2a signaling complex.
    Lukas SM; Kroe RR; Wildeson J; Peet GW; Frego L; Davidson W; Ingraham RH; Pargellis CA; Labadia ME; Werneburg BG
    Biochemistry; 2004 Aug; 43(31):9950-60. PubMed ID: 15287722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assay development and case history of a 32K-biased library high-content MK2-EGFP translocation screen to identify p38 mitogen-activated protein kinase inhibitors on the ArrayScan 3.1 imaging platform.
    Trask OJ; Baker A; Williams RG; Nickischer D; Kandasamy R; Laethem C; Johnston PA; Johnston PA
    Methods Enzymol; 2006; 414():419-39. PubMed ID: 17110205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight MK2 inhibitors: a tough nut to crack!
    Schlapbach A; Huppertz C
    Future Med Chem; 2009 Oct; 1(7):1243-57. PubMed ID: 21426101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitogen-activated protein kinase-activated protein kinase 2 (MK2) in skeletal muscle atrophy and hypertrophy.
    Norrby M; Tågerud S
    J Cell Physiol; 2010 Apr; 223(1):194-201. PubMed ID: 20049871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
    Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
    J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting.
    Gurgis FM; Ziaziaris W; Munoz L
    Mol Pharmacol; 2014 Feb; 85(2):345-56. PubMed ID: 24296859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.
    Nickischer D; Laethem C; Trask OJ; Williams RG; Kandasamy R; Johnston PA; Johnston PA
    Methods Enzymol; 2006; 414():389-418. PubMed ID: 17110204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors.
    Bauer SM; Kubiak JM; Rothbauer U; Laufer S
    Methods Mol Biol; 2016; 1360():123-48. PubMed ID: 26501907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIF signaling stimulates translation of TNF-alpha mRNA via prolonged activation of MK2.
    Gais P; Tiedje C; Altmayr F; Gaestel M; Weighardt H; Holzmann B
    J Immunol; 2010 May; 184(10):5842-8. PubMed ID: 20375303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct role of MAPKAPK-2 in the regulation of TNF gene expression by Toll-like receptor 7 and 9 ligands.
    Thuraisingam T; Xu YZ; Moisan J; Lachance C; Garnon J; Di Marco S; Gaestel M; Radzioch D
    Mol Immunol; 2007 Jul; 44(14):3482-91. PubMed ID: 17485113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of two distinct regions of p38 MAPK required for substrate binding and phosphorylation.
    Gum RJ; Young PR
    Biochem Biophys Res Commun; 1999 Dec; 266(1):284-9. PubMed ID: 10581204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the molecular basis of MK2-p38α signaling complex assembly: insights into protein-protein interaction by molecular dynamics and free energy studies.
    Yang Y; Liu H; Yao X
    Mol Biosyst; 2012 Aug; 8(8):2106-18. PubMed ID: 22648002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2).
    Olsson H; Sjö P; Ersoy O; Kristoffersson A; Larsson J; Nordén B
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4738-40. PubMed ID: 20643547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element.
    Hitti E; Iakovleva T; Brook M; Deppenmeier S; Gruber AD; Radzioch D; Clark AR; Blackshear PJ; Kotlyarov A; Gaestel M
    Mol Cell Biol; 2006 Mar; 26(6):2399-407. PubMed ID: 16508014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.